This week's roundup of Houston innovators includes Steffie Tomson of Getaway Sticks ad Ed Pettitt and Paresh Patel of InnoGrid. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from innovative merchandise to microgrid technology — recently making headlines in Houston innovation.

Steffie Tomson, founder of Getaway Sticks

Steffie Tomson founded a company to prioritize comfort — without sacrificing style — for women on the go. Photo via getawaysticks.com

Houstonian Steffie Tomson, a neuroscientist by trade and the founder and CEO of footwear startup Getaway Sticks, had an idea for a different kind of shoe — one that was redesigned to prioritize women’s comfort.

“I thought, ‘why can’t we start with a sneaker material and then build a heel around it?’” she tells InnovationMap. “I started just slicing everyone else’s shoes and now I’m more convinced than ever that our shoe is different.”

Tomson was inspired to design the inaugural shoe for Getaway Sticks after her own struggle with heels, walking in the bustling Texas Medical Center from building to building for meetings. As a mom of two and a problem solver, she knew there had to be a better mousetrap. Click here to read more.

Ed Pettitt and Paresh Patel join the Houston Innovators Podcast to discuss InnoGrid's potential impact on equitable power. Photos courtesy of InnoGrid

With an unstable energy grid, two Houstonians know at least one solution in the evolving energy industry: Microgrids.

Ed Pettitt and Paresh Patel co-founded InnoGrid, a social enterprise working to establish community microgrids in lower income areas — neighborhoods that are most at risk of devastating power outages.

"We want to convert the commercial microgrid model for low and moderate income and undresourced residential communities," Patel explains on the latest episode of the Houston Innovators Podcast. Click here to read more and stream the episode.


Ed Pettitt and Paresh Patel join the Houston Innovators Podcast to discuss InnoGrid's potential impact on equitable power. Photos courtesy of InnoGrid

Houston founders aim to provide equity through energy resiliency

Houston innovators podcast episode 143

As temperatures climb and devastating natural disasters continue to test the power grid, two Houston innovators have a solution: Smart microgrids.

"Microgrids have been around for a very long time," Paresh Patel, co-founder of InnoGrid, says on the Houston Innovators Podcast. "We're primed here in Houston and in Texas to really see microgrids go mainstream. ... People want to see that they have control and are in charge of their own power."

Patel co-founded InnoGrid with Ed Pettitt and a few other collaborators following the 2020 Houston Climathon. The social enterprise is working to establish community microgrids in lower income areas — neighborhoods that are most at risk of devastating power outages.

"We want to convert the commercial microgrid model for low and moderate income and undresourced residential communities," Patel explains.

And there's never been a better time to shine a spotlight on microgrids as a solution to unreliable power systems, Pettitt says.

"We're dealing with massive inflation — costs are going up especially in food and energy," he explains on the show. "Even prior to this time of inflation, electricity prices in the US were expected to increase across the board. Hundreds of thousands of people right now today are being pushed below the poverty line because of increased energy costs. We need to be more creative in how we upgrade our infrastructure."

And the current grid system is well overdue for an upgrade. The microgrid system fits right in with the shared economy we live in today, Patel says, and it allows for more generation of energy that is decentralized, digitalized, decarbonized, and democratized — the four Ds as he says.

"When you consider our current grid system, it is a vestige of the industrial revolution — it's 140 years old. That business model is ripe for innovation," Patel says.

"We need to accelerate deployment of microgrid models," he continues. "I don't think we can afford to update our current grid system — it'll cost $2 trillion."

Most importantly, these microgrids need to be implemented in an equitable way, the founders say, and InnoGrid has its eyes on one Houston area in particular. The Innovation Corridor, which spans from the Texas Medical Center to Downtown Houston, would be the ideal region to deploy the technology.

"If you look at the innovation corridor, it forms the spine of the city. You have so many important municipal buildings, first-responding organizations, and a large amount of affordable housing in the area. There's critical resources here that we want to make sure the lights stay on in power disasters," Pettit says. "One of the things we believe at InnoGrid is that where you live shouldn't determine whether or not you survive a national weather event. We want to make sure we provide energy stability in the communities that need it most."

To make this dream into a reality, InnoGrid needs the right partnerships and support in the area — and the founders have made progress. InnoGrid recently participated in the Ion Smart and Resilient Cities Accelerator and has a relationship with Greentown Houston across the street.

Eventually, as Pettit says, InnoGrid wants to help lead Houston to becoming a hub for microgrid innovation.

"We're looking at other cities — like Chicago and Boston — and how they've deployed their microgrids and making sure we're bringing those best practices in Houston," Pettit says. "Eventually we want to be the leader in developing these microgrid best practices as the energy capital of the world."

Patel and Pettitt share more about InnoGrid and microgrid technology on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”